Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 2:22 PM
Ignite Modification Date:
2025-12-24 @ 2:22 PM
NCT ID:
NCT00000995
Eligibility Criteria:
Inclusion Criteria
Concurrent Medication:
Allowed:
* Symptomatic therapy such as analgesics, antihistamines, antiemetics, and antidiarrheal agents, or other supportive therapy may be administered as deemed necessary by the responsible investigator. For fever, the following regimens should be used:
* If fever above 39.0 degrees C, antipyretic therapy will be administered employing aspirin, 650 mg orally every 4 hours x 3 doses, or until fever falls below 39.0 degrees C.
* If fever of higher than 39.0 degrees C occurs for 2 consecutive days, the patient may be premedicated with aspirin.
Exclusion Criteria
* Active alcohol or drug abuse.
Co-existing Condition:
Excluded:
* Patients with other life-threatening and uncontrolled opportunistic infections on enrollment.
Patients with the following prior conditions are excluded if they:
* Have other life-threatening and uncontrolled opportunistic infections on enrollment.
Prior Medication:
Excluded within 1 week of study entry:
* Systemic therapy with antimetabolite.
* Cytotoxic drug.
* Interferon.
* Immunologic modulators.
* Corticosteroids.
* Nucleoside analogs other than zidovudine (AZT).
* Excluded within 2 weeks of study entry:
* Therapy for any other opportunistic infections.
* Excluded within 2 months of study entry:
* Ribavirin.
Prior Treatment:
Excluded within 2 weeks of study entry (for treatment group I):
* Blood transfusion.
* Excluded within 1 month of study entry (for treatment groups II and III):
* Blood transfusion.
All patients must be:
* Able to provide informed consent.
* Likely to be available for follow-up for at least 4 months.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00000995
Study Brief:
Protocol Section:
NCT00000995